To modulate T cell function for cancer therapy one challenge is to selectively attenuate regulatory but not conventional CD4+ T cell subsets (Treg and Tconv). In this study we show how a functional dichotomy in Class IA PI3K isoforms in these two subsets of CD4+ T cells be exploited to target Treg while leaving Tconv intact. Studies employing isoform-specific PI3K inhibitors and a PI3Kδ-deficient mouse strain revealed that PI3Kα and PI3Kβ were functionally redundant with PI3Kδ in Tconv. Conversely, PI3Kδ was functionally critical in Treg, acting there to control TCR signaling, cell proliferation and survival. Notably, in a murine model of lung cancer, co-administration of a PI3Kδ-specific inhibitor with a tumor-specific vaccine decreased numbers of suppressive Treg and increased numbers of vaccine-induced CD8 T-cells within the tumor microenvironment, eliciting potent anti-tumor efficacy. Overall, our results offer a mechanistic rationale to employ PI3Kδ inhibitors to selectively target Treg and improve cancer immunotherapy.
Introduction:
Decreasing the numbers and/or function of regulatory T-cells (Tregs) is needed to produce better therapeutic outcomes for cancer patients. The ideal Treg-targeting approach should be selective to maintain specifically in the frame of cancer immune therapy for which maintenance of a potent effector arm of the immune system is vital. Several approaches have been tested to deplete or inactivate Tregs [1] [2] [3] [4] , but these strategies do not provide selective inhibition of Tregs and may result in a decrease of effector T-cells [5] .
Understanding the signaling pathways regulating conventional T-cells (Tconvs) and Tregs activation, function and survival can help to design drugs that could selectively modulates Tregs and Tconvs. PI3K-Akt is an important pathway involved in signaling downstream of the T-cell receptor (TCR) and regulates proliferation, cell metabolism and cell growth, and as we have previously shown, it is differentially regulated in these CD4 T-cell subsets [6] [7] [8] [9] [10] [11] . Furthermore, it was recently reported that inhibition of the PI3Kδ isoform results in a decrease in Tregs number and delayed tumor growth in animal models [12] . However, the role of the PI3K isoforms in the regulation of Tregs and Tconvs is not fully understood. Here we hypothesized that there may be a differential role of Class IA PI3K isoforms in Tconv and Treg cell regulation.
The Class IA PI3K family consists of a heterodimeric complex of 110-kD catalytic subunits, p110α, β, or δ, with a regulatory subunit (p85α, p55α, p50α, p85β, or p55γ) [7, 13, 14] . The PI3K 110α and β subunits are ubiquitously expressed while p110δ expression is restricted to hematopoietic cells [7] . Cell death by apoptosis is a major regulator of hematopoietic cell homeostasis. B-cell lymphoma 2 (BCL-2) family proteins, which have either pro-or antiapoptotic activities, have been studied intensively for the past decade owing to their importance in the regulation of apoptosis [1] . Myeloid cell leukemia 1 (Mcl-1), an anti-apoptotic member of the Bcl-2 family [2] , is critical for survival of Treg cells, and it has been shown that, the loss of this antiapoptotic protein caused fatal autoimmunity [3] . Mcl-1 is tightly regulated by glycogen synthase kinase. The glycogen synthase kinase 3 (GSK3α/GSK3β) is a ubiquitously expressed serine/threonine kinase, and regulates a wide variety of functions, including metabolism, cell proliferation, cell differentiation and apoptosis and is reported to be required for Mcl-1 degradation [4] . GSK3β is a downstream target of PI3k-Akt signaling pathway and usually remains active in cells; however PI3K induced activation of Akt results in the phosphorylation (S9) of GSK-3β that inhibits its activity [5, 6] . The differential role of class IA PI3K isoform in regulating the survival and apoptosis of Tregs and Tconvs has not been elucidated yet.
Here, we report that Class IA PI3K isoforms play different roles in Tregs and Tconvs. We found that in contrast to Tregs that are primarily dependent on the PI3Kδ isoform, in Tconvs PI3Kδ is necessary, and in contrast to the situation in Tregs, PI3Kα and β provide a redundant pathway to PI3Kδ, ensuring the presence of alternative pathways to provide a robust effector function when needed to eliminate any assault on the immune system. We have also evaluated the translation of these findings in vivo on therapeutic efficacy by assessing the effect of treatment with PI3Kδ inhibitor on the antitumor immune response.Our findings clarify the role of the PI3K isoforms in CD4 T-cell TCR signaling and offer a further understanding of the development of selective strategies for the modulation of different CD4 T-cell subsets in the frame of immunotherapy.
Material and Methods:
Animals: C57BL/6 female 6-8-week-old mice were purchased from Jackson Laboratory (Bar Harbor, ME). P110delta-PI3K-D910A (kinase-dead) PI3Kδ KO mice was purchased from Charles River, Wilmington, MA and bred under pathogen-free conditions in the Augusta University animal facility. Foxp3-GFP mice were housed and bred under pathogen-free conditions in the Augusta University animal facility. All procedures were carried out in accordance with approved institutional animal protocols.
Antibodies: All fluorophore-labeled antibodies were purchased from BD Biosciences (San Jose, CA).
PI3K inhibitors: A66 (PI3Kα inhibitor; IC 50 of 32nM) [15, 16] , TGX-221 (PI3Kβ inhibitor; IC 50 of 5nM) [16, 17] , and CAL-101 (PI3Kδ inhibitor; IC 50 of 2.5nM) [18] , GDC-0941 (PAN PI3K inhibitor) [19] were purchased from Selleckchem, (Houston, TX) The IC 50 for each isoform is listed in (Supplementary Table 1 ).
Western Blotting (WB):
Total protein lysates were collected in RIPA buffer. Forty micrograms of lysates were run on SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were probed with primary antibodies (1:1000 dilutions) overnight at 4 o C and incubated with secondary antibodies (1:5000 dilution) for one hour at room temperature. Chemiluminescence was performed with Pierce reagents (Rockford, IL). according to the manufacturer's protocol (Life Technologies, NY). Cells were stimulated with and without inhibitors in the presence of 10μg/mL plate-bound anti-CD3, 2.5μg/mL soluble anti-CD28, and 100 IU/mL IL-2. For negative control (non-stimulated), cells were cultured in 100 IU/mL IL-2. After 3 days, cells were stained with fixable live/dead cell stain (Life Technologies, NY), fixed and permeabilized using the mouse Foxp3 buffer kit according to the manufacturer's instructions (BD Bioscience, San Jose, CA) and stained with anti-CD4-FITC and anti-Foxp3-AlexaFluor 647. For pAkt (S473) and pS6 (S244) analysis, the signal was amplified using a biotin-conjugated donkey anti-rabbit antibody (BD Biosciences) and streptavidin-PE. After staining, cells were acquired on a LSRII SORP flow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star).
T-cell Stimulation Flow cytometry analysis and in vitro

Tumor cell lines:
TC-1 cell line was a gift from Prof. T.C. Wu, Johns Hopkins University, Department of Pathology, and Baltimore, MD [20] . Briefly, TC-1 tumor cell line was generated from lung epithelial cells immortalized with HPV16 E6 and E7. Cell line authentication was carried out by morphology and flow cytometry 4 months prior to the first submission of the manuscript [21] .
Cell lines used in this study were routinely tested for contamination by PCR. All cell culture stocks were stored in liquid nitrogen. The growth of tumors formed from these cells is enhanced by Tregs. 
RESULTS
Class IA PI3K isoform differentially regulate TCR signaling and proliferation of regulatory T-cells and Conventional T-cells
We recently reported that several inhibitors that target PI3K and its downstream effector, Akt, selectively inhibit the in vitro proliferation of human and murine Treg when compared to Tconv.
This selective decrease in Treg proliferation provided us with a potential strategy to modulate the Treg/Tconv balance in vivo [10] . However, the exact mechanism of PI3K/Akt regulation in these subtypes has not been fully elucidated. The differential sensitivity of Tregs and Tconvs could be an outcome of disparate expression level of the PI3K isoforms in Tregs and Tconvs. We therefore checked the expression level of different PI3K isoforms in Tregs and Tconvs. We found no significant differences in protein expression patterns of the PI3K subunits, p85α, To gain a more complete understanding of the differential role of class IA PI3K isoform in Tregs and Tconvs, we tested the effect of specific PI3K isoform inhibition on the proliferation of these T-cell subtypes. Using Class IA Isoform specific inhibitors, we found that inhibiting PI3Kα or PI3Kβ has no effect on either Tregs or Tconvs proliferation as shown in Supplementary figure Furthermore, there was no significant differences in Tconvs obtained from the two mice strains.
These data demonstrate that TCR signaling in Tregs is exclusively dependent on PI3Kδ but not on PI3Kα or PI3Kβ, while in Tconvs, no specific isoform was found to be dominant in TCR downstream signaling. Tconv and on the proliferation of these two cells types. We tested the effect of the PI3Kδ inhibitor after stimulation with anti-CD3/anti-CD28 in a 3-day culture in media containing 100 IU/mL of IL2, with titrated amounts of CAL-101. Similar to the effect on mouse cells, we found that PI3Kδ inhibition led to a significant decreased level of pAkt in Tregs but not Tconv and significant abrogation of Tregs proliferation, without affecting Tconvs, in a concentrationdependent manner ( Figure 1H and 1I) . Based on the reproducibility of the data in human, we believe that using specific PI3Kδ inhibitor would be a reasonable approach to enhance cancer immunetherapy.
PI3K isoform differentially regulate the frequency of T-cell subsets in tumor bearing mice
After demonstrating that the inhibition of PI3Kδ isoform but not PI3Kα or β impairs TCR signaling in Tregs and not Tconvs in vitro, we next tested whether this specificity is translated in an in vivo model. We selected TC-1 [20] syngeneic mouse model which is a Treg-dependent tumor model [22] , and the frequency of Tregs increases significantly in tumor bearing mice compared to non-tumor mice ( Figure 2B ). In addition, TC-1 expresses PI3Kα and PI3Kβ, but do not express detectable levels of p110δ ( Figure 2C ). Consequently, specific PI3K isoform inhibitors were tested in the TC-1 syngeneic mouse tumor model. Mice were treated with a single dose of the inhibitors 10 days after tumor implantation (Figure 2A ). Mice were sacrificed 3 or 6 days after treatment and the level of splenic Tregs was assessed. We found that inhibition of PI3Kδ with CAL-101 led to a dose dependent inhibition of Tregs in the spleen with significant reduction at 10mg/Kg on day 3 after treatment ( Figure 2D ). In contrast, inhibition of PI3Kα or β had no significant effects on splenic Tregs with either a 2mg/kg or 10 mg/kg dose on day 3 to further confirm this we tested whether the inhibition of PI3Kδ induces apoptosis in Tregs.
Using Annexin V binding assay, we found that frequency of Annexin V positive (apoptotic) cells increased with increasing concentrations of CAL-101 (Supplementary figure S7A) .
To understand the molecular mechanism by which PI3Kδ inhibition selectively induces apoptosis leading to reduced survival of Tregs, we next evaluated the effect of specific PI3K isoform inhibition on the anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1), which is critical for the survival of T-cells including Tregs [24] and is rapidly degraded when cells undergo apoptosis in response to various stimuli [25- 
PI3Kδ is required for the GSK-3b and Mcl-1 dependent survival pathway in Tconvs, and is compensated by PI3Kα and PI3Kβ
We have shown that inhibition of PI3Kδ selectively activates GSK-3β in Tregs, which favors the degradation of anti-apoptotic protein Mcl-1 leading to the decreased survival of Tregs, and had no effect on Tconvs. To understand the role of PI3K isoforms in the regulation of survival in Tconvs, we first examine the effect of PAN PI3K inhibitor. We found that, survival pathway of S7C) . We next investigated whether inhibition of any 2 PI3K isoforms affect survival of Tconvs.
We found that combining inhibition of both PI3Kα and PI3Kβ did not induce apoptosis and did not affect the survival ( Figure 5C and supplementary figure S7B ). As expected, there was no effect on Mcl-1 and pGSK-3β (Figure 5D ), which further provide evidences that, in absence of PI3Kα and PI3Kβ, PI3Kδ is sufficient to regulate the survival of Tconvs.
On the other hand, combining PI3Kδ inhibitor with either PI3Kα or PI3Kβ inhibitor significantly reduced the survival ( Figure 5C ), induces apoptosis (supplementary figure S7C) , and decreased Mcl-1protein with inhibited pGSK-3β of Tconvs ( Figure 5D ).
Together, all these data suggest that PI3Kδ is sufficient for survival signaling in Tconvs, however, in contrast to Tregs, in Tconvs, PI3Kα and PI3Kβ combined can compensate for the absence of PI3Kδ (Figure 5E ). Importantly, we also showed that these finding translated into therapeutic efficacy. We found that inhibiting PI3Kδ with CAL101 synergistically enhanced the tumor suppression and survival effect of antigen specific vaccine. While evaluating immunologic mechanisms responsible for this potent therapeutic outcome, we found that CAL-101 resulted in decreasing Tregs tumor infiltration resulting in significant increase of tumor-infiltrating antigen specific CD8 T-cells.
Inhibition of
Based on above, here we show the molecular reasons that Tregs but not Tconv are depended on
PI3Kδ and that such findings can have a major translational and clinical therapeutic impact. 
